Indapta Therapeutics Email Format

Biotechnology ResearchTexas, United States11-50 Employees

Indapta Therapeutics is a Houston-based biotechnology company focused on developing allogeneic gamma-NK cell therapies for cancer. Its NK cells show strong antibody-dependent cellular cytotoxicity and are designed to be paired with IgG1 monoclonal antibodies, antibody-drug conjugates, or innate immune cell engagers to boost anti-tumor activity. The company operates in the cancer immunotherapy space, aiming to supplement existing antibody-based treatments with a cellular therapy platform.

Lead candidate IDP-023 has FDA Fast Track designation for non-Hodgkin's lymphoma and multiple myeloma, reflecting its focus on these blood cancers. A recent development is a clinical study collaboration with Sanofi on a multiple myeloma program, signaling ongoing partnership activity to advance its research.

Sign up for free to view info

Company overview Employee directory